Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil

British Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2009, Pages 535-540

  Sakugawa, Takashi ^a   Miura, Masatomo ^b   Hokama, Nobuo ^a   Suzuki, Toshio ^b   Tateishi, Tomonori ^c   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Enantiomer; Fexofenadine; P glycoprotein; Verapamil

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; HUMAN; HUMAN TISSUE; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; TERFENADINE; VERAPAMIL; YOUNG ADULT;

EID: 65349166687     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03396.x     Document Type: Article

References (21)

1. Kim RB. Transporters and xenobiotic disposition. Toxicology 2002 181 182 : 291 7.
2. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999 27 : 866 71.
3. Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 2002 91 : 2622 35.
4. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 2002 42 : 1269 74.
5. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002 71 : 11 20.
6. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004 308 : 438 45.
7. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000 59 : 301 21.
8. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998 19 : 455 63.
9. Miura M, Uno T, Tateishi T, Suzuki T. Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal 2007 43 : 741 5.
10. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007 19 : 223 7.
11. Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008 65 : 693 700.
12. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000 293 : 376 82.
13. Tsuruo T, Iida H, Naganuma K, Tsukagoshi S, Sakurai Y. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 1983 43 : 808 13.
14. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983 43 : 2267 72.
15. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marié FN, Benmiloud M, Sturtz F. Verapamil increases the survival of patients with anthracycline- resistant metastatic breast carcinoma. Ann Oncol 2000 11 : 1471 6.
16. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987 84 : 7735 8.
17. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003 1 5.
18. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001 69 : 114 21.
19. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006 79 : 218 30.
20. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005 77 : 17 23.
21. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther 2003 74 : 423 36.